Understanding the Cali Fund: new expectations for biotech’s use of DSI
Global DSI rules have changed – is your company ready?
Watch this insightful webinar explaining the landmark decision made at COP16 to establish a multilateral benefit-sharing mechanism for the use of Digital Sequence Information (DSI) and the Cali Fund. This pivotal development has significant implications for biotech and life sciences companies utilising (non-human) Digital Sequence Information (DSI) in their operations.
While there remains a lack of clarity surrounding certain aspects of the decision, the Cali Fund is already operational, and companies using DSI are expected to contribute to it now. Watch our webinar to gain crucial insights into what this means for your business, including the expectations of UK biotech companies to contribute to the Fund.
Speakers:
Linda Bedenik
What does your role at BIA involve?
Linda leads on intellectual property (IP), engineering biology (EngBio), R&D and innovation policy and animal research. She provides the secretariat to BIA's two advisory committees - Intellectual Property (IPAC) and Engineering Biology (EBAC) as well as the All-Party Parliamentary Group (APPG) for Life Sciences.
Previous experience & achievements
Prior to joining BIA, Linda worked as a Policy Analyst at a non-profit looking into university-business collaboration and knowledge exchange in the UK and as a researcher at a public policy-focused think tank identifying challenges to state-level public service delivery and rural health in India. Linda has an MA in Global Political Economy from the University of Sussex.
If you could invite any scientist or entrepreneur to dinner, who would it be and why?
Santos-Dumont and the Wright Brothers – to have them settle the debate over who flew first.
